Lynda D Roman

List of Publications by Year
in descending order

148 papers	2,316 citations	236612 25 h-index	344852 36 g-index
153 all docs	153 docs citations	153 times ranked	2528 citing authors

#	Article	IF	Citations
1	Metastatic extent-specific prognosis of women with stage IVB cervical cancer: multiple versus single distant organ involvement. Archives of Gynecology and Obstetrics, 2023, 307, 533-540.	0.8	3
2	Utilization of sentinel lymphÂnode biopsy in the early ovarian cancer surgery. Archives of Gynecology and Obstetrics, 2023, 307, 525-532.	0.8	5
3	Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. Archives of Gynecology and Obstetrics, 2022, 306, 283-287.	0.8	3
4	Proposal of a simple 2-hand technique at cesarean hysterectomy for placenta accreta spectrum. Archives of Gynecology and Obstetrics, 2022, 305, 1-5.	0.8	3
5	Sentinel lymph node biopsy for vulvar melanoma: trends in tumor stage-specific utilization. American Journal of Obstetrics and Gynecology, 2022, 226, 438-440.	0.7	4
6	Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. Brachytherapy, 2022, 21, 141-150.	0.2	1
7	Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. Gynecologic Oncology, 2022, 164, 46-52.	0.6	12
8	Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. Gynecologic Oncology, 2022, 164, 651-657.	0.6	6
9	Validation of the 2021 FIGO staging schema for advanced vulvar cancer. International Journal of Gynecological Cancer, 2022, 32, 474-479.	1.2	5
10	Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer. Gynecologic Oncology, 2022, 165, 264-269.	0.6	4
11	Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. Gynecologic Oncology, 2022, , .	0.6	1
12	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. European Journal of Surgical Oncology, 2022, 48, 1407-1413.	0.5	6
13	Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification. Gynecologic Oncology, 2022, 165, 361-368.	0.6	4
14	Population incidence and characteristics of secondary breast cancer after uterine cancer: a competing risk analysis. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	0
15	Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. Gynecologic Oncology, 2022, 165, 428-436.	0.6	5
16	Trends and characteristics of ovarian conservation at hysterectomy for young women with cervical cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 273, 59-64.	0.5	2
17	Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia. American Journal of Obstetrics and Gynecology, 2022, 227, 255.e1-255.e18.	0.7	6
18	Sideâ€toâ€end reanastomosis after lowâ€anterior resection (STELAR): Outcomes, feasibility, and description of procedure performed by a gynecologic oncology service. Journal of Surgical Oncology, 2022, 126, 563-570.	0.8	1

#	Article	IF	Citations
19	Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US. JAMA Oncology, 2022, 8, 1213.	3.4	18
20	Utility of the 3-tier grouping system for survival discriminatory ability in stage IIA cervical cancer. European Journal of Surgical Oncology, 2021, 47, 331-337.	0.5	0
21	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecologic Oncology, 2021, 160, 586-601.	0.6	56
22	Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. American Journal of Obstetrics and Gynecology, 2021, 224, 319-321.	0.7	12
23	Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma. Annals of Surgical Oncology, 2021, 28, 1740-1748.	0.7	6
24	National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 459-470.	1.3	11
25	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2021, 160, 32-39.	0.6	20
26	Association Between Adjuvant Therapy and Survival in Stage IIâ€“III Endometrial Cancer: Influence of Malignant Peritoneal Cytology. Annals of Surgical Oncology, 2021, 28, 7591-7603.	0.7	10
27	Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. Gynecologic Oncology, 2021, 161, 39-45.	0.6	13
28	Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature. Gynecologic Oncology, 2021, 161, 70-77.	0.6	13
29	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. Gynecologic Oncology, 2021, 161, 414-421.	0.6	4
30	Recent changes in demographics and outcomes of cervical cancer in the United States. Archives of Gynecology and Obstetrics, 2021, 304, 1-3.	0.8	9
31	Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. International Journal of Gynecological Cancer, 2021, 31, 991-1000.	1.2	7
32	Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema. American Journal of Obstetrics and Gynecology, 2021, 224, 574-584.	0.7	30
33	Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery. Radiation Oncology, 2021, 16, 123.	1.2	1
34	Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. American Journal of Obstetrics and Gynecology, 2021, 225, 399.e1-399.e32.	0.7	24
35	Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. Gynecologic Oncology, 2021, 161, 710-719.	0.6	9
36	Clinicoâ€pathological significance of suspicious peritoneal cytology in endometrial cancer. Journal of Surgical Oncology, 2021, 124, 687-698.	0.8	2

#	Article	IF	Citations
37	Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. Gynecologic Oncology, 2021, 162, 43-49.	0.6	20
38	Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	0
39	Risk of Upper-body Adverse Events in Robot-assisted Total Laparoscopic Hysterectomy for Benign Gynecologic Disease. Journal of Minimally Invasive Gynecology, 2021, 28, 1585-1594.e1.	0.3	3
40	Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. European Journal of Cancer, 2021, 157, 59-62.	1.3	4
41	Survival effect of intra-operative tumor spillage during minimally invasive hysterectomy for early-stage endometrial cancer: a call for research. International Journal of Gynecological Cancer, 2021, 31, 308-309.	1.2	5
42	Minimally Invasive Surgery and Surgical Volume-Specific Survival and Perioperative Outcome: Unmet Need for Evidence in Gynecologic Malignancy. Journal of Clinical Medicine, 2021, 10, 4787.	1.0	5
43	Proposing the 3â€tier staging system for improving prognostication in Stage I uterine leiomyosarcoma. Journal of Surgical Oncology, 2021, 123, 1099-1108.	0.8	0
44	Intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer: A survey study on experience and practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 267, 256-261.	0.5	5
45	Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease. Biomedicines, 2021, 9, 1935.	1.4	7
46	Treatment and outcome of placenta percreta: Primary cesarean hysterectomy versus conservative management. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 244, 201-203.	0.5	8
47	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. American Journal of Obstetrics and Gynecology, 2020, 222, 484.e1-484.e15.	0.7	16
48	Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecologic Oncology, 2020, 156, 100-106.	0.6	14
49	Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. Journal of Surgical Oncology, 2020, 121, 402-409.	0.8	16
50	Vesicoureteral Injury during Benign Hysterectomy: Minimally Invasive Laparoscopic Surgery versus Laparotomy. Journal of Minimally Invasive Gynecology, 2020, 27, 1354-1362.	0.3	15
51	Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecologic Oncology, 2020, 159, 869-876.	0.6	3
52	Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period. Gynecologic Oncology, 2020, 158, 390-396.	0.6	14
53	Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecologic Oncology, 2020, 159, 43-51.	0.6	23
54	Financial viewpoint of minimally invasive radical hysterectomy for early cervical cancer: another disadvantage?. International Journal of Gynecological Cancer, 2020, 30, 1464-1464.	1.2	0

#	Article	IF	Citations
55	Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. International Journal of Gynecological Cancer, 2020, 30, 1-9.	1.2	13
56	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	1.2	12
57	Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence. European Journal of Cancer, 2020, 140, 149-150.	1.3	7
58	Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic. Gynecologic Oncology, 2020, 158, 37-43.	0.6	23
59	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology, 2020, 158, 59-65.	0.6	12
60	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cordâ€“Stromal Tumors: A Contemporary Review. Cancers, 2020, 12, 1398.	1.7	24
61	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncology, 2020, 6, 1110.	3.4	37
62	Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. Archives of Gynecology and Obstetrics, 2020, 301, 1235-1245.	0.8	6
63	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. Current Oncology Reports, 2020, 22, 28.	1.8	11
64	Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology, 2020, 157, 3-11.	0.6	13
65	Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. Gynecologic Oncology, 2020, 157, 173-180.	0.6	11
66	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology, 2020, 157, 21-28.	0.6	8
67	Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. American Journal of Obstetrics and Gynecology, 2020, 223, 103.e1-103.e13.	0.7	31
68	Implementation of multidisciplinary practice change to improve outcomes for women with placenta accreta spectrum. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 246, 194-196.	0.5	10
69	Cesarean radical hysterectomy for cervical cancer in the United States: a national study of surgical outcomes. American Journal of Obstetrics and Gynecology, 2020, 222, 507-511.e2.	0.7	4
70	Significance of lymph node ratio on survival of women with borderline ovarian tumors. Archives of Gynecology and Obstetrics, 2020, 301, 1289-1298.	0.8	8
71	Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. Archives of Gynecology and Obstetrics, 2020, 301, 863-866.	0.8	4
72	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. American Journal of Obstetrics and Gynecology, 2020, 223, 721.e1-721.e18.	0.7	28

#	Article	IF	Citations
73	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. European Journal of Cancer, 2020, 133, 33-46.	1.3	34
74	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. Gynecologic Oncology, 2019, 154, 505-515.	0.6	11
75	Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles. International Journal of Molecular Sciences, 2019, 20, 4999.	1.8	13
76	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	0.6	16
77	Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies. Gynecologic Oncology Reports, 2019, 30, 100497.	0.3	17
78	Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis. Journal of Clinical Medicine, 2019, 8, 714.	1.0	3
79	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. Gynecologic Oncology, 2019, 154, 169-176.	0.6	8
80	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. American Journal of Obstetrics and Gynecology, 2019, 220, 469.e1-469.e13.	0.7	30
81	Tumor characteristics and outcome of uterine carcinosarcoma in women aged â‰¥80 years. Surgical Oncology, 2019, 29, 25-32.	0.8	1
82	Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. Gynecologic Oncology, 2019, 154, 45-52.	0.6	15
83	Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Archives of Gynecology and Obstetrics, 2019, 299, 1641-1649.	0.8	5
84	Utero-ovarian preservation and overall survival of young women with early-stage borderline ovarian tumors. Archives of Gynecology and Obstetrics, 2019, 299, 1651-1658.	0.8	15
85	Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. Gynecologic Oncology, 2019, 153, 368-375.	0.6	39
86	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecologic Oncology, 2019, 153, 230-237.	0.6	16
87	Temporal trends and characteristics of suicide among women with gynecologic malignancy in the United States. Gynecologic Oncology Reports, 2019, 30, 100510.	0.3	6
88	Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic Oncology, 2019, 152, 605-611.	0.6	4
89	Significance of abnormal peritoneal cytology on survival of women with stage Iâ€“II endometrioid endometrial cancer. Gynecologic Oncology, 2018, 149, 301-309.	0.6	43
90	Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma. Archives of Gynecology and Obstetrics, 2018, 297, 749-756.	0.8	3

#	Article	IF	Citations
91	Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecologic Oncology, 2018, 148, 267-274.	0.6	14
92	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. Journal of Surgical Oncology, 2018, 117, 488-496.	0.8	15
93	Reply. American Journal of Obstetrics and Gynecology, 2018, 218, 264.	0.7	0
94	Impact of lymphoâ€vascular space invasion on tumor characteristics and survival outcome of women with lowâ€grade serous ovarian carcinoma. Journal of Surgical Oncology, 2018, 117, 236-244.	0.8	8
95	Trends in single women with malignancy of the uterine cervix in United States. Journal of Gynecologic Oncology, 2018, 29, e24.	1.0	7
96	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. American Journal of Obstetrics and Gynecology, 2018, 219, 461.e1-461.e18.	0.7	22
97	Clinical utility of CA-125 in the management of uterine carcinosarcoma. Journal of Gynecologic Oncology, 2018, 29, e88.	1.0	4
98	Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. Journal of Gynecologic Oncology, 2018, 29, e91.	1.0	34
99	Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study. BMC Cancer, 2018, 18, 970.	1.1	8
100	Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States. Journal of Gynecologic Oncology, 2018, 29, e85.	1.0	11
101	Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. Gynecologic Oncology, 2018, 151, 250-256.	0.6	4
102	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. Surgical Oncology, 2018, 27, 433-440.	0.8	12
103	Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecologic Oncology, 2018, 150, 501-508.	0.6	11
104	Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e69.	1.0	27
105	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 2756-2766.	0.7	5
106	Trends of uterine carcinosarcoma in the United States. Journal of Gynecologic Oncology, 2018, 29, e22.	1.0	47
107	Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecologic Oncology Reports, 2018, 25, 98-101.	0.3	23
108	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 3676-3684.	0.7	14

#	Article	IF	Citations
109	Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget, 2018, 9, 28757-28771.	0.8	38
110	Phase II clinical trial of eribulin (E) in advanced/recurrent cervical cancer.. Journal of Clinical Oncology, 2018, 36, 5526-5526.	0.8	0
111	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecologic Oncology, 2017, 144, 329-335.	0.6	20
112	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology, 2017, 144, 496-502.	0.6	27
113	Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy. Gynecologic Oncology, 2017, 145, 41-49.	0.6	3
114	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecologic Oncology, 2017, 145, 78-87.	0.6	31
115	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2017, 129, 139-151.	1.2	31
116	Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities?. Archives of Gynecology and Obstetrics, 2017, 295, 1459-1468.	0.8	29
117	Patient compliance for postoperative radiotherapy and survival outcome of women with stage I endometrioid endometrial cancer. Journal of Surgical Oncology, 2017, 116, 482-491.	0.8	11
118	Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer. Gynecologic Oncology, 2017, 144, 515-523.	0.6	10
119	Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. Gynecologic Oncology, 2017, 147, 558-564.	0.6	37
120	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecologic Oncology, 2017, 147, 565-571.	0.6	9
121	Single Marital Status and Infectious Mortality in Women With Cervical Cancer in the United States. International Journal of Gynecological Cancer, 2017, 27, 1737-1746.	1.2	8
122	Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. Obstetrics and Gynecology, 2017, 130, 403-410.	1.2	33
123	Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. American Journal of Obstetrics and Gynecology, 2017, 217, 580.e1-580.e10.	0.7	19
124	A pilot study in using deep learning to predict limited life expectancy in women with recurrent cervical cancer. American Journal of Obstetrics and Gynecology, 2017, 217, 703-705.	0.7	19
125	Timing of Intrauterine Manipulator Insertion During Minimally Invasive Surgical Staging and Results of Pelvic Cytology in Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2016, 23, 234-241.	0.3	25
126	Endoplasmic reticulum stress in complex atypical hyperplasia as a possible predictor of occult carcinoma and progestin response. Gynecologic Oncology, 2016, 143, 650-654.	0.6	12

#	Article	IF	Citations
127	Significance of venous thromboembolism in women with cervical cancer. Gynecologic Oncology, 2016, 142, 405-412.	0.6	20
128	Tumor Characteristics and Survival Outcome of Endometrial Cancer Arising in Adenomyosis: An Exploratory Analysis. Annals of Surgical Oncology, 2016, 23, 959-967.	0.7	25
129	Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.. Journal of Clinical Oncology, 2016, 34, 5547-5547.	0.8	7
130	A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2016, 34, 5578-5578.	0.8	4
131	Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer. Journal of Surgical Oncology, 2015, 112, 669-676.	0.8	42
132	Molecular Analysis of Mixed Endometrioid and Serous Adenocarcinoma of the Endometrium. PLoS ONE, 2015, 10, e0130909.	1.1	23
133	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecologic Oncology, 2015, 138, 332-338.	0.6	35
134	Escalation of Oncologic Services at the End of Life Among Patients With Gynecologic Cancer at an Urban, Public Hospital. Journal of Oncology Practice, 2015, 11, e163-e169.	2.5	16
135	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecologic Oncology, 2015, 136, 198-204.	0.6	17
136	Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series. Gynecologic Oncology Reports, 2015, 13, 36-39.	0.3	6
137	Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer. Obstetrics and Gynecology, 2015, 125, 424-433.	1.2	53
138	Effects of imiquimod on vulvar Paget's disease: A systematic review of literature. Gynecologic Oncology, 2015, 139, 165-171.	0.6	59
139	Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecologic Oncology, 2015, 139, 261-267.	0.6	51
140	Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clinical Immunology, 2015, 161, 197-208.	1.4	21
141	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 2015, 51, 1978-1988.	1.3	44
142	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	1.1	82
143	Phase II clinical trial of eribulin in advanced or recurrent cervical cancer (CC).. Journal of Clinical Oncology, 2015, 33, TPS5617-TPS5617.	0.8	0
144	A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. Gynecologic Oncology, 2014, 132, 517-525.	0.6	22

#	Article	IF	Citations
145	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2014, 133, 473-479.	0.6	53
146	Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. American Journal of Obstetrics and Gynecology, 2014, 210, 366.e1-366.e5.	0.7	24
147	Validation of a Multivariate Serum Profile for Epithelial Ovarian Cancer Using a Prospective Multi-Site Collection. Nature Precedings, 2010, , .	0.1	1
148	Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer, 2001, 91, 90-100.	2.0	68